Aggressive clinical course of large cell neuroendocrine carcinoma of the ampulla of Vater.

Ampulla of Vater large cell type neuroendocrine tumor

Journal

Northern clinics of Istanbul
ISSN: 2536-4553
Titre abrégé: North Clin Istanb
Pays: Turkey
ID NLM: 101684520

Informations de publication

Date de publication:
2021
Historique:
received: 23 01 2019
accepted: 14 05 2019
entrez: 25 2 2021
pubmed: 11 7 2019
medline: 11 7 2019
Statut: epublish

Résumé

A 78-year-old male patient with a history of the right hemicolectomy due to the adenocarcinoma was admitted by the complaint of epigastric discomfort. Laboratory data showed an increase in liver biochemistries (aspartate aminotransferase (AST): 159 IU/L, alanine aminotransferase (ALT):235 IU/L, alkaline phosphatase (ALP): 350 IU/L, gamma-glutamyl transferase (GGT): 911 IU/L, total bilirubin: 1.55 mg/dl and direct bilirubin: 0.82 mg/dl). Endoscopic retrograde cholangiopancreatiography (ERCP) administered after the gastrointestinal (GI) upper endoscopy was compatible with the tumoral lesion, and biopsy confirmed 'neuroendocrine carcinoma'. Pylorus-preserving pancreaticoduodenectomy (PPPD) was performed with R0 resection. Pathologic evaluation revealed a 1,5 cm tumor of large cell neuroendocrine carcinoma (LCNEC). Five months later, biopsy of suspicious lesions in the liver was documented as 'high-grade neuroendocrine carcinoma metastasis'. He was referred to the oncology for chemotherapy, but, unfortunately, he expired three months later. Large cell neuroendocrine carcinoma (LCNECs) of the ampulla of Vater might have an aggressive clinical course despite radical resections involving lymph node dissections. Small tumor size and lymph node negativity are not reliable factors for this tumor type.

Identifiants

pubmed: 33629034
doi: 10.14744/nci.2019.36002
pii: NCI-8-97
pmc: PMC7881429
doi:

Types de publication

Case Reports

Langues

eng

Pagination

97-100

Informations de copyright

Copyright: © 2021 by Istanbul Northern Anatolian Association of Public Hospitals.

Déclaration de conflit d'intérêts

Conflict of Interest: No conflict of interest was declared by the authors.

Références

Neoplasia. 2017 Dec;19(12):991-1002
pubmed: 29091800
Int J Surg Case Rep. 2017;31:132-138
pubmed: 28160741
Arch Pathol Lab Med. 2010 Nov;134(11):1692-6
pubmed: 21043824
Surg Endosc. 2012 Apr;26(4):920-5
pubmed: 22011948
Pancreas. 2010 Aug;39(6):799-800
pubmed: 20664477
JOP. 2012 Sep 10;13(5):470-5
pubmed: 22964952
Case Rep Oncol Med. 2013;2013:930359
pubmed: 24368955
J Chin Med Assoc. 2008 Oct;71(10):536-40
pubmed: 18955190

Auteurs

Recep Ercin Sonmez (RE)

Department of General Surgery, Istanbul Medeniyet University Faculty of Medicine, Istanbul, Turkey.

Fatih Buyuker (F)

Department of General Surgery, Istanbul Medeniyet University Faculty of Medicine, Istanbul, Turkey.

Rabia Burcin Girgin (RB)

Department of Pathology, Istanbul Medeniyet University Faculty of Medicine, Istanbul, Turkey.

Turgut Tunc Eren (TT)

Department of General Surgery, Istanbul Medeniyet University Faculty of Medicine, Istanbul, Turkey.

Gurhan Bas (G)

Department of General Surgery, Istanbul Medeniyet University Faculty of Medicine, Istanbul, Turkey.

Orhan Alimoglu (O)

Department of General Surgery, Istanbul Medeniyet University Faculty of Medicine, Istanbul, Turkey.

Classifications MeSH